4 terminated, 3 completed, 1 unknown, 1 withdrawn. 8 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow HSPPC-96: new trials by email Literature Review of HSPPC-96 trials Research Report on HSPPC-96
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 gp96, Temozolomide, radiotherapy - Glioma of Brain | Phase 2 | Unknown | Cure&Sure Biotech Co., LTD | 150 | 2019-08-21 | 2020-03-12 |
| Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Pembrolizumab, HSPPC-96, Temozolomide - Glioblastoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 90 | 2017-09-21 | 2025-08-08 |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma ipilimumab, HSPPC-96 - Melanoma | Phase 1 / Phase 2 | Withdrawn | Rabih Said | 2015-12-01 | 2016-01-25 | |
| Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery HSPPC-96, bevacizumab - Recurrent Glioblastoma, Recurrent Adult Brain Tumor | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 90 | 2013-06-19 | 2025-01-24 |
| Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence HSPPC-96 - Renal Cell Carcinoma | Phase 2 | Terminated | Agenus Inc. | 12 | 2010-01-01 | 2021-06-03 |
| HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM HSPPC-96, Temozolomide, Standard Surgical Resection - Brain and Central Nervous System Tumors | Phase 2 | Completed | University of California, San Francisco | 70 | 2009-06-29 | 2021-03-24 |
| GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma HSPPC-96, Standard Surgical Resection - Brain and Central Nervous System Tumors | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 96 | 2005-11-18 | 2021-05-13 |
| Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer HSPPC-96 - Kidney Cancer, Renal Cell Carcinoma | Phase 3 | Terminated | Agenus Inc. | 600 | 2005-05-01 | 2012-09-07 |
| Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer HSPPC-96 - Non-Small-Cell Lung Carcinoma, Lung Cancer | Phase 2 | Completed | Agenus Inc. | 20 | 2003-09-01 | 2009-03-09 |
Glioblastoma (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Central Nervous System Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioma (1) · Gliosarcoma (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1)
Agenus Inc. (3) · University of California, San Francisco (2) · Alliance for Clinical Trials in Oncology (1) · Cure&Sure Biotech Co., LTD (1) · National Cancer Institute (NCI) (1) · Rabih Said (1)
United States (7) · Canada (2) · China (1) · United Kingdom (1)
Jennifer Clarke, MD (2) · Christopher G Wood, MD, FACS (1) · Ian Parney, MD, PhD (1) · Kevin Camphausen, M.D. (1) · Louis Lacombe, MD, FRCSC (1) · Orin Bloch, MD (1) · Rabih Said, MD, MPH (1) · Ronald P Kaufman, MD, FACS (1)
PMID 24335700, PMID 28193626, PMID 42396282
P50CA097257 (1), R01CA164714 (1), U10CA031946 (1)